STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Karolinska Development AB (STO:KDEV): Pharmanest AB today announced that the first patient has been dosed in an open label pharmacokinetic study with its drug candidate SHACT, a product developed for pain relief in connection with intrauterine device (IUD) insertion. Karolinska Development AB owns 55% of Pharmanest.
